LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and
FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This …

Regulatory T (Treg) cells maintain immune homeostasis by inhibiting abnormal/overactive
immune responses to both autogenic and nonautogenic antigens. Treg cells play an …

Tumor immunotherapy is considered to be a novel and promising therapy for tumors and it
has recently become a hot research topic. The clinical success of tumor immunotherapy has …

Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and
few effective treatment options. Nonetheless, recent positive phase III trial results for immune …

Background The role of immunotherapy in cancer is now well-established, and therapeutic
options such as checkpoint inhibitors are increasingly being approved in many cancers such …

Simple Summary Malignant pleural mesothelioma is an invasive and drug-resistant tumor
related to asbestos exposure, with limited therapy options. It is associated with an …

Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity.
Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes …

Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos
exposure and associated with a very poor prognosis. After more than a decade without new …

Simple Summary Malignant Pleural Mesothelioma (MPM) is a highly aggressive, therapy-
resistant cancer with a well-established inflammatory etiology and has no cure. Immune …

Simple Summary Malignant pleural mesothelioma is a cancer of the lung lining, normally
caused by asbestos, that develops decades after exposure. Chemotherapy, and recently …